Conflicts of interest None reported.
Mortality of bullous pemphigoid in the first year after diagnosis: a retrospective study in a Spanish medical centre
Article first published online: 22 DEC 2012
© 2012 The Authors. Journal of the European Academy of Dermatology and Venereology © 2012 European Academy of Dermatology and Venereology
Journal of the European Academy of Dermatology and Venereology
Volume 28, Issue 4, pages 500–506, April 2014
How to Cite
Gual, A., Mascaró, J.M., Rojas-Farreras, S., Guilabert, A., Julià, M. and Iranzo, P. (2014), Mortality of bullous pemphigoid in the first year after diagnosis: a retrospective study in a Spanish medical centre. Journal of the European Academy of Dermatology and Venereology, 28: 500–506. doi: 10.1111/jdv.12065
Funding sources This study was supported in part by a grant from the Hospital Clinic de Barcelona (Ajut a la Recerca Josep Font). The sponsors had no role in the design and conduct of the study; in the collection, analysis, and interpretation of data; or in the preparation, review, or approval of the manuscript.
- Issue published online: 18 MAR 2014
- Article first published online: 22 DEC 2012
- Received: 13 June 2012; Accepted: 9 November 2012
- Hospital Clinic de Barcelona (Ajut a la Recerca Josep Font
Background Prognosis of patients with bullous pemphigoid (BP) is controversial, with a 1-year mortality rate ranging from 6% to 48%.
Objective To determine the mortality rate of a large cohort of patients with BP and to identify prognostic factors associated with early mortality.
Methods Patients diagnosed with BP between January 1, 1990 and December 31, 2010 in a referral unit for blistering skin diseases at a university hospital in Spain were studied retrospectively. Outcome measures were mortality rate during the first year after diagnosis, standardized mortality rate and poor prognostic factors.
Results A total of 101 patients were included in the study. The mean patient age at diagnosis was 77.8 years, and 52 (51.5%) were men. Overall mortality during the first year was 12.9%. We found a standardized mortality ratio of 2.33 [CI95 = (1.25–4.03)]. Advanced age (patient group >80 years old) was the only risk factor for lethal outcome found, with a multivariate risk estimate of 1.09 [CI95 = (1.02–1.16)]. No significant association with mortality was detected for comorbidities, hospitalization history or treatment received for BP.
Conclusions We found an increased mortality of our BP patients compared with the general population. The mortality rate of BP patients was 2.3 times the expected rate. Observed mortality rate was lower than described in previous European studies. Advanced age impacts the prognosis of patients with BP. Specific treatment for BP appeared not to influence survival.